STOCK TITAN

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Nevro Corp. (NVRO) will report its first-quarter 2024 financial results on May 7, 2024, after the market closes. The company, known for its chronic pain treatment solutions, will host an earnings conference call to discuss the results. Investors and analysts can access the live webcast on the company's Investor Relations website. For those without internet access, a conference call option is available.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.

The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time.

For those parties that do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and providing conference ID 6973396:

U.S. domestic participant dial-in number (toll-free):         1-(888) 596-4144

International participant dial-in number:                           1-(646) 968-2525

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.

Nevro recently added a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI joint") pain and now provides the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.

Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.

To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.

Investors and Media:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com

.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-first-quarter-2024-financial-results-and-host-earnings-conference-call-on-may-7-2024-302119092.html

SOURCE Nevro Corp.

FAQ

When will Nevro Corp. release its first-quarter 2024 financial results?

Nevro Corp. will release its first-quarter 2024 financial results after the market closes on May 7, 2024.

What does Nevro Corp. specialize in?

Nevro Corp. specializes in delivering comprehensive, life-changing solutions for the treatment of chronic pain.

How can investors access the conference call discussing Nevro Corp.'s financial results?

Investors can access the live webcast and replay of the conference call in the Investor Relations section of Nevro Corp.'s website at Events & Presentations.

What are the dial-in numbers for the conference call if one does not have internet access?

For those without internet access, the conference call can be accessed by calling the U.S. domestic participant dial-in number (toll-free): 1-(888) 596-4144 or the international participant dial-in number: 1-(646) 968-2525, and providing conference ID 6973396.

NEVRO CORP.

NYSE:NVRO

NVRO Rankings

NVRO Latest News

NVRO Stock Data

381.85M
35.44M
3.91%
108.64%
11.54%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About NVRO

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.